Eli Lilly and Novo Nordisk currently dominate the market for the new class of GLP-1 receptor agonist medications, which work by mimicking the effect of a gut hormone that reduces appetite.

Eli Lilly announced that it is expanding its offerings of its hit weight loss drug Zepbound on Tuesday, a few days after the Food and Drug Administration lifted a shortage on Novo Nordisk’s Wegovy and ...

Novo Nordisk is doing exceptionally well in the face of the challenges posed by Eli Lilly ... which is a long-acting growth hormone. Thanks to less frequent injections and the fact that it ...

During five years of share price growth, Eli Lilly achieved compound earnings per share (EPS) growth of 19% per year. This EPS growth is slower than the share price growth of 47% per year ...

We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we are going to take a look at where Eli Lilly and Company (NYSE ...